eed inhibitor

MAK683 hydrochloride embryonic ectodermal development (EED) inhibitor, also a potent PRC2 inhibitor, blocked cancer cell proliferation (IC50=1.014nM), with IC50 values of 59, 26, and 89 nM measured in EED Alphascreen, ELISA, and LC-MS assays, respectively.

MAK683 is an inhibitor of embryonic ectoderm development (EED) (IC50s: 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay).

Boc-GABA-OH serves as a PROTAC linker essential for synthesizing UNC6852, an EED-targeted PROTAC[1].

PROTAC EED degrader-1, a PROTAC targeting EED (pKD = 9.02), is an inhibitor of polycomb repressive complex 2 (PRC2) with a pIC50 of 8.17.

PROTAC EED degrader-2 is a PROTAC targeting EED (pKD of 9.27) and an inhibitor of polycomb repressive complex 2 (PRC2) with a pIC50 of 8.11.

UNC6852 contains an EED ligand (IC50 = 247 nM) and a von Hippel-Lindau ligand and is a selective polycomb repressive complex 2 (PRC2) degrader based on PROTAC.

EZH2-IN-23 (Compound 25) is an EZH2 inhibitor, exhibiting potent enzymatic inhibition against the PRC2 complex [EZH2, EED, SUZ12, AEBP2, and RbAp48] with an IC50 of 0.8 nM. It inhibits H3K27 trimethylation in cells with an IC50 of 40 nM. In rats, EZH2-IN-23 demonstrates excellent pharmacokinetic properties, achieving 100% oral bioavailability.

EED-IN-3 is an orally active inhibitor of EED. It effectively binds with EED (IC50 = 0.62 μM) to inhibit PRC2 and reduces H3K27me3 levels. EED-IN-3 selectively inhibits PC3 cells with an IC50 of 3.69 μM and significantly suppresses colony formation and migration. This compound is useful for prostate cancer research.

EEDi-5285, an orally active and highly potent inhibitor targeting embryonic ectoderm development (EED) protein, exhibits anti-cancer activity. It demonstrates exceptional efficacy with an IC50 value of 0.2 nM, indicating robust binding affinity to the EED protein.

EEDi-5285 TFA(2488952-40-3 Free base) is a potent and orally active small molecule inhibitor of embryonic ectodermal development (EED) with an IC50 value of 0.2 nM and excellent pharmacokinetics.

EED226 is a potent, selective, and orally bioavailable embryonic ectoderm development (EED) inhibitor with an IC50 of 22 nM.

FTX-6058 is a potent orally active inhibitor targeting Embryonic Ectoderm Development (EED). It effectively induces HbF protein expression in both cell and murine models. This compound holds significant potential for researching select hemoglobinopathies such as sickle cell disease and β-thalassemia.

FTX-6058 hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED), with the ability to induce HbF protein expression in both cell and murine models. This compound is particularly valuable in the research of select hemoglobinopathies, such as sickle cell disease and β-thalassemia.

EEDi-5273 is a highly potent and orally efficacious inhibitor of EED, with an approximate IC50 value of 0.2 nM. This compound exhibits exceptional activity, capable of achieving complete and persistent regression of tumors.

EED ligand 1 is a highly versatile, potent, and effective inhibitor that specifically targets the EED subunit of the polycomb repressive complex 2 (PRC2) methyltransferase.

Pociredir (FTX-6058) is a potent, selective, and orally active inhibitor of embryonic ectoderm development (EED) with a KD of 0.163 nM, possessing research value in inflammatory conditions or hemoglobinopathies such as sickle cell disease (SCD).